根据名称进行药物检索

Acunivive 30 Injection System与肾功能不全

Acunivive 30 Injection System与肾功能不全安全配伍检测的结果。

检测结果:

Acunivive 30 Injection System <> 肾功能不全

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

使用酮咯酸的禁用于患有晚期肾功能损害或风险增加肾脏衰竭受到大量损耗。酮咯酸是一种有效的非甾体抗炎药(非甾体). 使用的药物可能与肾毒性，包括海拔在血清肌酸酐和面包，管坏死，腎小球炎、肾乳头坏死、急性间质性肾炎、肾病综合症和肾衰竭。在患者与腎前条件的肾灌注可以依赖于功能肾前列腺素、非甾体抗炎药可沉淀物的公开肾脏代偿失调，通过与剂量相关的抑制作用的前列腺素的综合。病人在最大的风险，为这种反应包括老年患者和那些肾功能受损、心脏衰竭、肝功能障碍，或者大量和/或钠损耗(例如，由于利尿剂). 治疗与酮咯酸应给予谨慎地在这样的病人和血容量和低钠血应该加以纠正之前发起的治疗。临床监测的肾功能是建议在治疗。如果肾功能下降或肾衰竭的发生，迅速停止酮咯酸治疗通常会导致恢复到预处理状态。由于酮咯酸及其代谢物被消除肾、减少一半的正常剂量最高的60毫克/天是建议在患有中度损害肾功能，以避免药物积累。

来源

Brocks DR, Jamali F "Clinical pharmacokinetics of ketorolac tromethamine." Clin Pharmacokinet 23 (1992): 415-27
Jung D, Mroszczak E, Bynum L "Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration." Eur J Clin Pharmacol 35 (1988): 423-5
Pearce CJ, Gonzalez FM, Wallin JD "Renal failure and hyperkalemia associated with ketorolac tromethamine." Arch Intern Med 153 (1993): 1000-2
Buller GK, Perazella MA "Acute renal failure and ketorolac." Ann Intern Med 127 (1997): 493
Perneger TV, Whelton PK, Klag MJ "Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs." N Engl J Med 331 (1994): 1675-9
Haragsim L, Dalal R, Bagga H, Bastani B "Ketorolac-induced acute renal failure and hyperkalemia: report of three cases." Am J Kidney Dis 24 (1994): 578-80
Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
Fong J, Gora ML "Reversible renal insufficiency following ketorolac therapy." Ann Pharmacother 27 (1993): 510-2
Boras-Uber LA, Brackett NC Jr "Ketorolac-induced acute renal failure." Am J Med 92 (1992): 450-2
"Product Information. Toradol (ketorolac)." Roche Laboratories, Nutley, NJ.
Martinez JJ, Garg DC, Pages LJ, et al "Single dose pharmacokinetics of ketorolac in healthy young and renal impaired subjects." J Clin Pharmacol 27 (1987): 722
Feldman HI, Kinman JL, Strom BL "Acute renal failure and ketorolac." Ann Intern Med 127 (1997): 493-4
Myles PS, Power I "Does ketorolac cause postoperative renal failure: how do we assess the evidence?" Br J Anaesth 80 (1998): 420-1
Buck ML, Norwood VF "Ketorolac-induced acute renal failure in a previously healthy adolescent." Pediatrics 98 (1996): 294-6
Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, Cho DK "Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans." Drug Metab Dispos 15 (1987): 618-26
Jung D, Mroszczak EJ, Wu A, Ling TL, Sevelius H, Bynum L "Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine." Pharm Res 6 (1989): 62-5
Kelley M, Bastani B "Ketorolac-induced acute renal failure and hyperkalemia." Clin Nephrol 44 (1995): 276-7
Quan DJ, Kayser SR "Ketorolac induced acute renal failure following a single dose." J Toxicol Clin Toxicol 32 (1994): 305-9
Litvak KM, McEvoy GK "Ketorolac, an injectable nonnarcotic analgesic." Clin Pharm 9 (1990): 921-35
Aitken HA, Burns JW, McArdle CS, Kenny GNC "Effects of ketorolac trometamol on renal function." Br J Anaesth 68 (1992): 481-5
Feldman HI, Kinman JL, Berlin JA, et al. "Parenteral ketorolac: the risk for acute renal failure." Ann Intern Med 126 (1997): 193-9
Jallad NS, Garg DC, Martinez JJ, Mroszczak EJ, Weidler DJ "Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly." J Clin Pharmacol 30 (1990): 76-81